Laverty joins Eisai

Share this article:
Eisai has named longtime pharma communicator Robert Laverty to the newly created position of VP of US communications.

Laverty joins Eisai from Novartis, where he served as VP, global communications, malaria initiatives.

A 22-year industry veteran, Laverty has previously held several other executive titles at Novartis including VP, external communication and VP, global pharma media relations. 

Prior to joining Novartis, Laverty worked in several corporate policy, corporate affairs, and product public affairs positions at Bristol-Myers Squibb Company.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...